The Food and Drug Administration approved the opioid-induced constipation treatment developed by Progenics Pharmaceuticals Inc. (Nasdaq: PGNX) and Valeant Pharmaceuticals (NYSE: VRX). Shares of Progenics soared $1.20 to close at $6.14 while Valeant stock climbed $1.03 to close at $24.57.
FDA approves Progenix treatment
July 20, 2016 at 19:00 PM EDT
